Will IPB be the next Carnarvon?

|

Published 01-MAY-2019 11:50 A.M.

|

5 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The years 2018 and 2019 have definitely featured contrasting conditions for IPB Petroleum (ASX:IPB) given that the company entered the fiscal 2018 facing the continuation of a pessimistic oil price outlook and constrained industry funding.

Foreign exchange rates were also working against our producers with the Australian dollar fetching more than US$0.80, well above recent levels.

Against this backdrop, management was able to not only maintain its valuable assets in the prolific Browse Basin, but complete valuable survey activity which has increased the technical merits of its assets, lowered possible commercial risks and increased the chances of farm-outs and/or financing at reasonable terms which you can read about in the current quarterly.

Importantly, the information gathered provided the foundation for a substantial increase to the prospective resource at Idris (WA-424-P), offshore north-west Australia in the Browse Basin.

These were all important developments given that industry funding for new exploration and appraisal opportunities is fundamental to IPB Petroleum’s strategy, in that the company relies on farm-outs and funding to undertake the more expensive permit work commitments such as drilling wells.

It is important to note though that IPB is in a position to generate income from oil sales from early stage exploration activity, a distinct advantage compared with its more speculative peers.

2019 heralds boom Australian dollar oil price

IPB entered 2019 as a much stronger company with a clear vision and a range of options.

In terms of those issues beyond management’s control, they couldn’t be better.

The recent rally in the Brent crude price saw it cruise past US$70 per barrel, while the Australian dollar declined significantly against the US dollar, a perfect scenario for IPB.

From an oil price perspective, the halcyon days were between 2011 and 2014 when the commodity mainly traded in a range between US$100 per barrel US$120 per barrel.

For the majority of that period, the AUD:USD exchange rate fluctuated between US$0.95 and US$1.10.

The mid-ranges of the commodity price and the foreign exchange rate equates to an Australian dollar oil price of $107 per barrel.

With the Australian dollar now hovering in the vicinity of US$0.70, and last Thursday slipping below that mark for the second time this year, it seems reasonable to apply that rate.

This equates to an Australian dollar oil price of $100 per barrel relative to a Brent crude price of US$70 per barrel.

Consequently, we may as well be back in the heady days of 2011-14 when pricing ASX-listed companies that will be selling oil in US dollars.

This is evidenced by the share price performances of the big three, Woodside Petroleum Ltd (ASX: WPL – black line), Santos Ltd (ASX:STO) and Oil Search Ltd (ASX:OSH).

The following 12 month share price chart demonstrates the recovery that started as 2019 ticked over.

This has significance for oil companies involved in exploration as there is normally a flow on effect as value becomes more difficult to find in the larger companies.

Consequently, a company such as IPB Petroleum is perfectly positioned to benefit from investors looking to identify under the radar stocks.

Best address in a sought-after region

What is likely to bring IPB under the spotlight quicker than many other smaller players is the quality of its assets.

Exploration Permit WA-424-P is wholly owned and operated by IPB, and over the last six months the company has continued to progress its farm-out plans, with access to the company’s data room and seismic project provided to certain interested parties.

Management recently noted that ‘a small number of parties’ remain interested in the process.

IPB is positive about the potential of its permits and interest by industry participants who may wish to pursue a collaborative initiative.

However, management has decided to focus its near-term strategy on the self-determining drilling, logging and testing project (DLT project) at Idris and Gwydion.

As indicated below, Gwydion is flanked to the west by world-class gas fields (red) such as Icthys, and within those there are also oil fields (green).

Carnarvon Petroleum (ASX:CVN) makes for an interesting point of comparison as its assets offshore Western Australia, stretch from north of the Browse Basin South to the Barrow Sub-Basin offshore Exmouth.

While the company had interests in a number of wells, it was the Dorado discovery that put it on the map, sending its share price from about 15 cents to more than 60 cents in July/August last year.

Dorado is one of the group’s more southerly situated assets in proven territory, similar to IPB.

DLT Project to define reservoir size

During the December half, IPB successfully completed a feasibility study into its proposed DLT Project.

This involves the proposed drilling of a well at Idris followed by a flow test of a subsequent horizontal well over an extended period to assess the extent of the oil discovered by Gwydion-1.

The objective of the project is to help better define reservoir size and resources, which has been difficult to refine on the current 3D data set given the stratigraphic nature of the reservoir.

The oil produced during the flow test is to be transferred to a chartered tanker and subsequently sold.

The generation of income from oil sales is an important aspect to bear in mind for an emerging player such as IPB given that it will be used to repay proposed debt funding, with any surplus then distributed to IPB and possible vendor financiers.

IPB has already commenced debt financing activities and the environmental approval process, and as the company ticks these boxes there could be associated share price accretion.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X